BioAlliance Pharma Announces The Launch Of Sitavig® In The United States By Its Partner Innocutis

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the launch of Sitavig® (acyclovir Lauriad®) in the United States by its commercial partner, Innocutis Holdings LLC, and the granting of a new U.S. Sitavig® patent by the United States Patent and Trademark Office.

Help employers find you! Check out all the jobs and post your resume.